Clinical Trial Update: Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of SAR443216 in relapsed/refractory HER2-expressing solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Lung Cancer

Drugs mentioned

• SAR443216 (SAR443216)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant, Breast Cancer | Phase 1 | Status: TERMINATED